Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients
Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients
corcept医疗宣布在ADA第84届科学会议上公布了CATALYST临床试验的结果；该研究显示，难以控制的2型糖尿病患者有24%的高皮质醇综合征患病率；该研究对1,055名患者进行了迄今为止最大的研究。
- Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes"
- With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes
- Results demonstrate a hypercortisolism prevalence rate of 24 percent in this patient population
- CATALYST临床试验的结果在美国糖尿病协会第84次科学会议的特色板块"难以控制的2型糖尿病患者的高皮质醇血症患病率"上进行了展示。
- CATALYST是迄今为止最大、最严谨的研究，共招募了1055名患有难以控制的2型糖尿病患者。
- 结果表明，该患者人群中高皮质醇血症的患病率为24%。
资讯热榜
更新时间